Radiofrequency ablation in combination with CD73 inhibitor AB680 reduces tumor growth and enhances anti-tumor immunity in a syngeneic model of pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma presents a 5-year overall survival rate of 11%, placing an imperative need for the discovery and application of innovative treatments. Radiofrequency ablation represents a promising therapy for PDA, as studies show it induces coagulative necrosis and a host adaptive...

Descripción completa

Detalles Bibliográficos
Autores principales: Faraoni, Erika Y., Strickland, Lincoln N., O’Brien, Baylee J., Barraza, Joseph F., Thosani, Nirav C., Wray, Curtis J., Mills, Tingting W., Bailey-Lundberg, Jennifer M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486545/
https://www.ncbi.nlm.nih.gov/pubmed/36147911
http://dx.doi.org/10.3389/fonc.2022.995027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486545/
https://www.ncbi.nlm.nih.gov/pubmed/36147911
http://dx.doi.org/10.3389/fonc.2022.995027

Ejemplares similares